Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.31 |
| ▸ | EYA2 | O00167 | 1/20 | 0.31 |
| ▸ | APP | P05067 | 1/20 | 0.31 |
| ▸ | ACE | P12821 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.30 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | DRD1 | P21728 | 1/20 | 0.30 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.30 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.30 |
| ▸ | DRD3 | P35462 | 1/20 | 0.30 |
| ▸ | BLM | P54132 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14345486 | 1.00 | TDP1 (0.31) | TDP1EYA2APPACEMEN1 | |
| SCHEMBL5032518 | 1.00 | TDP1 (0.31) | TDP1EYA2APPACEMEN1 | |
| SCHEMBL12202775 | 0.95 | — | — | |
| SCHEMBL12202789 | 0.95 | — | — | |
| SCHEMBL3498361 | 0.94 | TDP1 (0.33) | TDP1EYA2APPACEKDM4E | |
| SCHEMBL3844876 | 0.90 | EPOR (0.33) | TDP1EYA2APPACEMEN1 | |
| SCHEMBL12694735 | 0.88 | TDP1 (0.33) | TDP1EYA2APPACEKDM4E | |
| SCHEMBL8058792 | 0.86 | CYP2D6 (0.35) | TDP1EYA2APPACEKDM4E | |
| SCHEMBL6511739 | 0.86 | CYP2D6 (0.35) | TDP1EYA2APPACEKDM4E | |
| SCHEMBL5033034 | 0.83 | MEN1 (0.34) | MEN1GAAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1935435-B1 | Blood pool agents for nuclear magnetic resonance diagnostics | BRACCO IMAGING SPA (IT) | 2017-09-06 | — | — | EP | disclosed |
| US-20140271465-A1 | MATRIX METALLOPROTEASE (MMP) TARGETED AGENTS FOR IMAGING AND THERAPY | MALLINCKRODT LLC (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140271465-A1 | MATRIX METALLOPROTEASE (MMP) TARGETED AGENTS FOR IMAGING AND THERAPY | MALLINCKRODT LLC (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140234211-A1 | SUPRAMOLECULAR AGGREGATES CONTAINING AMPHIPHILIC MONOMERS, CHELATING AGENTS AND PEPTIDES FOR USE FOR DRUG DELIVERY AND AS CONTRAST AGENTS | INVECTORS S.R.L. (IT) | 2014-08-21 | — | — | US | disclosed |
| US-20090130018-A1 | SUPRAMOLECULAR AGGREGATES CONTAINING CHELATING AGENTS AND BIOACTIVE PEPTIDES AS EFFECTIVE AND SELECTIVE DELIVERY TOOLS FOR DRUGS AND CONTRAST AGENTS IN MRI OR NUCLEAR MEDICINE | INVECTORS S.R.L. (IT) | 2009-05-21 | — | — | US | disclosed |
| EP-1140209-B1 | BLOOD POOL AGENTS FOR NUCLEAR MAGNETIC RESONANCE DIAGNOSTICS | BRACCO IMAGING SPA (IT) | 2008-08-20 | — | — | EP | disclosed |
| EP-1935435-A2 | Blood pool agents for nuclear magnetic resonance diagnostics | Bracco Imaging S.p.A (IT) | 2008-06-25 | — | — | EP | disclosed |
| EP-1898958-A2 | SUPRAMOLECULAR AGGREGATES CONTAINING CHELATING AGENTS AND BIOACTIVE PEPTIDES AS EFFECTIVE AND SELECTIVE DELIVERY TOOLS FOR DRUGS AND CONTRAST AGENTS IN MRI OR NUCLEAR MEDICINE | INBIOS S.r.l. (IT) | 2008-03-19 | — | — | EP | disclosed |
| US-20080058636-A1 | METHODS OF MYOCARDIAL IMAGING | EPIX PHARMACEUTICALS, INC. | 2008-03-06 | — | — | US | disclosed |
| US-20070293656-A1 | COLLAGEN BINDING PEPTIDES | EPIX PHARMACEUTICALS, INC. | 2007-12-20 | — | — | US | disclosed |
| EP-1259532-A1 | BILE ACIDS CONJUGATES WITH METAL ION CHELATES AND THE USE THEREOF | Bracco Imaging S.p.A. (IT) | 2002-11-27 | — | — | EP | disclosed |
| US-6461588-B1 | VASCULAR SYSTEMS | BRACCO IMAGING S.P.A. (IT) | 2002-10-08 | — | — | US | disclosed |
| US-6458337-B1 | Diagnostic imaging contrast agent with improved in serum relaxivity | DIBRA S.P.A (IT) | 2002-10-01 | — | — | US | disclosed |
| EP-1140209-A1 | BLOOD POOL AGENTS FOR NUCLEAR MAGNETIC RESONANCE DIAGNOSTICS | BRACCO IMAGING S.p.A. (IT) | 2001-10-10 | — | — | EP | disclosed |
| WO-2001064708-A1 | BILE ACIDS CONJUGATES WITH METAL ION CHELATES AND THE USE THEREOF | BRACCO IMAGING S.P.A. (IT) | 2001-09-07 | — | — | WO | disclosed |
| WO-2000038738-A1 | BLOOD POOL AGENTS FOR NUCLEAR MAGNETIC RESONANCE DIAGNOSTICS | BRACCO IMAGING S.P.A. (IT) | 2000-07-06 | — | — | WO | disclosed |
| EP-0760683-B1 | BILE ACID CONJUGATES, DERIVATIVES THEREOF WITH METAL COMPLEXES AND RELATED USES | BRACCO SPA (IT) | 2000-01-05 | — | — | EP | disclosed |
| US-5649537-A | CONJUGATION OF A BILE ACID WITH A CHELATING AGENT AND BI- OR TRIVALENT METALS; IMAGING OF THE HEPTATOBILIARY SYSTEM; NUCLEAR MAGNETIC RESONANCE | DIBRA S.P.A. (IT) | 1997-07-22 | — | — | US | disclosed |
| EP-0760683-A1 | BILE ACID CONJUGATES, DERIVATIVES THEREOF WITH METAL COMPLEXES AND RELATED USES | BRACCO S.p.A. (IT) | 1997-03-12 | — | — | EP | disclosed |
| WO-1995032741-A1 | BILE ACID CONJUGATES, DERIVATIVES THEREOF WITH METAL COMPLEXES AND RELATED USES | BRACCO S.P.A. (IT) | 1995-12-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140271465-A1 | MATRIX METALLOPROTEASE (MMP) TARGETED AGENTS FOR IMAGING AND THERAPY | MMP3, MMP26, MMP10 | TDP1 2813/4885EYA2 4733/4885APP 2964/4885 |
| US-20080058636-A1 | METHODS OF MYOCARDIAL IMAGING | FABP3, TNNI3, TNNT2 | TDP1 2596/4885EYA2 3335/4885APP 1412/4885 |
| US-20090130018-A1 | SUPRAMOLECULAR AGGREGATES CONTAINING CHELATING AGENTS AND BIOACTIVE PEPTIDES AS EFFECTIVE AND SELECTIVE DELIVERY TOOLS FOR DRUGS AND CONTRAST AGENTS IN MRI OR NUCLEAR MEDICINE | ORAI1, PICALM, IAPP | TDP1 3673/4885EYA2 4796/4885APP 362/4885 |
| US-20140234211-A1 | SUPRAMOLECULAR AGGREGATES CONTAINING AMPHIPHILIC MONOMERS, CHELATING AGENTS AND PEPTIDES FOR USE FOR DRUG DELIVERY AND AS CONTRAST AGENTS | GRPR, BRS3, BID | TDP1 3282/4885EYA2 3979/4885APP 2277/4885 |
| US-20070293656-A1 | COLLAGEN BINDING PEPTIDES | COL14A1, COL2A1, COL1A1 | TDP1 2478/4885EYA2 3112/4885APP 803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.